Multiple Myeloma

Matthew Crowley

Otterbein University, matthew.crowley@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn

Part of the Hemic and Lymphatic Diseases Commons, Medical Pathology Commons, and the Nursing Commons

Recommended Citation

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an authorized administrator of Digital Commons @ Otterbein. For more information, please contact digitalcommons07@otterbein.edu.
Introduction

Multiple myeloma is a rare and largely incurable malignant disease that affects the plasma cells. (Bianchi, & Anderson, 2014) New MM cases each year (Bianchi, and the second most common hematologic U.S. (Kuo, Fenves, Mehta, 2011). MM is incurable malignant disease that affects approximately 75% of patients (Al Farsi, 2013) Approximately 75% of patients (Al Farsi, 2013). Understanding the pathophysiology of Multiple Myeloma (MM) and treatment options in Oncology and Hematology nursing can be difficult. It is the goal of this poster to outline the pathophysiology, treatment options available to multiple myeloma patients.

Multiple myeloma accounts for about 10% of all hematologic malignancies in the U.S. (Gian, Fenees, Hartford, 2011). MM is the second most common hematologic malignancy with twenty-four thousand new MM cases each year (Bianchi, and Anderson, 2014).

Signs & Symptoms

- Bone pain and fractures
- Fatigue
- Increased infections
- Weakness and fatigue
- Restlessness
- Confusion
- Increased thirst
- Nausea and vomiting
- Loss of appetite
- Weight loss
- Impaired kidney function
- Increased or decreased urination

Fatigue is a commonly reported symptom of MM often thought to be a consequence of anemia (Brooker, Florman, Pekalski, Noon, & Bahlis, 2005). Anemia (mostly normocytic-normochromic) is seen in approximately 75% of patients (Al Farsi, 2013).

Pathophysiology

In normal physiology, mature plasma cells make up less than 5% of the bone marrow cells. Precursor cells, called plasma blasts and B lymphocytes are stimulated by antigens and cytokines then migrate to the bone marrow where they stop proliferating and begin to differentiate to mature plasma cells (Mangen, 2005). The majority of MM is preceded by a premalignant disease known as monoclonal gammopathy of undetermined significance (Manier, Sacco, Leleu, Ghobrial, & Roccaro, 2012). This monoclonal gammopathy is an expansion of a single clone of plasma cells (Ferreiro, 2011). The expansion of these cells crowds out healthy cells.

This proliferation of monoclonal plasma cells accumulates in the marrow which leads to secretion of cytokines by the tumor cells. Here in the microenvironment of the bone marrow the ability of myeloma cells to live and replicate is thought to occur (Mangen, 2005).

The majority of MM patients eventually relapse with all therapeutic options currently available (Lounest, Green, Dinh, Richardson, Anderson, & Mitulskie, 2013). Balance between bone resorption and bone formation is lost in many cases of MM, resulting in bone destruction and the development of osteolytic lesions (Mater et al., 2012). Bone health is a primary concern for MM patients.

Implications for Nursing Care

Treatment options include the use of monoclonal antibodies against specific surface molecules in MM patients (Lawasut et al., 2013). High-dose chemotherapy with autologous stem cell transplantation is the standard of therapy for patients newly diagnosed with multiple myeloma who are younger than age 70 or have no comorbidities (Tariman, & Estrella, 2005).

Nursing care occurs in multiple settings. “Nurses provide care and education to patients at all stages of the multiple myeloma (MM) disease continuum, from the premalignant stage and diagnosis all the way through survivorship to the end of life.” (Nizzielli, 2012) Patients present to routine exams, present to emergency department and as inpatients who are newly diagnosed with multiple myeloma who are diagnosed with multiple myeloma and as inpatients who are newly diagnosed with multiple myeloma.

Fatigue is a commonly reported symptom of MM often thought to be a consequence of anemia (Brooker, Florman, Pekalski, Noon, & Bahlis, 2005). Anemia (mostly normocytic-normochromic) is seen in approximately 75% of patients (Al Farsi, 2013).

References


Conclusion

Multiple Myeloma diagnosis and prognosis is viewed as incurable there remains many treatment options based on the stage of cancer, age and comorbidities. Patient goals should always be considered when developing treatment plans and discussing options. Early stages of the disease can yield many years of quality life with current treatments ranging from combination chemotherapy to bone marrow transplant. For end stage disease patients quality of life can be achieved through compassionate caring delivered by palliative measures and hospice care.